Almost 80% of Bitcoin transactions involve transfers smaller than 0.01 BTC, highlighting the prominence of small transfers on the network. However, this statistic only counts the number of transactions, not the volume of Bitcoin moved or the purpose behind these transfers. Therefore, it does not prove that Bitcoin is widely used for purchasing goods or services. Understanding Bitcoin's use in payments requires more detailed data on transaction purposes and values over time.
Bitcoin transaction sizes under 0.01 BTC make up nearly 80% of all transfers, providing context on the scale of small Bitcoin movements. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Oct 19, 2026 23:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 41 rose and 8 fell today. Notable movers include BCH at Rp5.011.670 with a 3.75% increase and a typical hold time of 69 days, XTZ at Rp5.463 up 3.51% with 100 days typical hold, and GRT at Rp432 rising 3.46%, all with varying Pluang order activity ratios.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
